The role of CR2 in autoimmunity

References

• Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 1990; 145: 2974–2983
   PubMed Web of Science ®Google Scholar
• Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein–Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984; 81: 4510–4514
   PubMed Web of Science ®Google Scholar
• Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358: 505–507
   PubMed Web of Science ®Google Scholar
• Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J 1991; 10: 919–926
   PubMed Web of Science ®Google Scholar
• Bouillie S, Barel M, Drane P, Cassinat B, Balbo M, Holers VM, Frade R. Epstein–Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Eur J Immunol 1995; 25: 2661–2667
   Google Scholar
• Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 1991; 173: 55–64
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: A CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med 1991; 173: 1083–1089
   Google Scholar
• Fujisaku A, Harley JB, Frank MB, Gruner BA, Frazier B, Holers VM. Genomic organization and polymorphisms of the human C3d/Epstein–Barr virus receptor. J Biol Chem 1989; 264: 2118–2125
   Google Scholar
• Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): Expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997; 159: 1557–1569
   PubMed Web of Science ®Google Scholar
• Tedder TF, Clement LT, Cooper MD. Expression of C3d receptors during human B cell differentiation: Immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol 1984; 133: 678–683
   PubMed Web of Science ®Google Scholar
• Uckun FM. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908–1923
   PubMed Web of Science ®Google Scholar
• Timens W, Boes A, Poppema S. Human marginal zone B cells are not an activated B cell subset: strong expression of CD21 as a putative mediator for rapid B cell activation. Eur J Immunol 1989; 19: 2163–2166
   PubMedGoogle Scholar
• Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol 1988; 141: 457–463
   PubMed Web of Science ®Google Scholar
• Luxembourg AT, Cooper NR. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J Immunol 1994; 153: 4448–4457
   PubMed Web of Science ®Google Scholar
• Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996; 271: 348–350
   PubMed Web of Science ®Google Scholar
• Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, Poe JC, Tedder TF. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol 2005; 175: 8011–8023
   Google Scholar
• Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998; 160: 1565–1572
   PubMed Web of Science ®Google Scholar
• Prechl J, Baiu DC, Horvath A, Erdei A. Modeling the presentation of C3d-coated antigen by B lymphocytes: Enhancement by CR1/2-BCR co-ligation is selective for the co-ligating antigen. Int Immunol 2002; 14: 241–247
   Google Scholar
• Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14: 169–179
   PubMed Web of Science ®Google Scholar
• Erdei A, Melchers F, Schulz T, Dierich M. The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur J Immunol 1985; 15: 184–188
   PubMedGoogle Scholar
• Melchers F., Erdei A., Schulz T., Dierich M.P. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 1985; 317: 264–267
   PubMed Web of Science ®Google Scholar
• Croix DA, Ahearn JM, Rosengard AM, Han S, Kelsoe G, Ma M, Carroll MC. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J Exp Med 1996; 183: 1857–1864
   PubMed Web of Science ®Google Scholar
• Fang Y, Xu C, Fu YX, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998; 160: 5273–5279
   PubMed Web of Science ®Google Scholar
• Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, Kelsoe G, Carroll MC. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998; 280: 582–585
   PubMedGoogle Scholar
• Reid RR, Woodcock S, Shimabukuro-Vornhagen A, Austen WG, Jr, Kobzik L, Zhang M, Hechtman HB, Moore FD, Jr, Carroll MC. Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol 2002; 169: 5433–5440
   PubMed Web of Science ®Google Scholar
• Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, Xia J, Zhou X, Howard RG, Rothstein TL, Carroll MC. Disruption of the CR2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996; 4: 251–262
   PubMed Web of Science ®Google Scholar
• Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, Goodnow CC, Carroll MC. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9: 721–731
   PubMed Web of Science ®Google Scholar
• Del Nagro CJ, Kolla RV, Rickert RC. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J Immunol 2005; 175: 5379–5389
   Google Scholar
• Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: A role for complement. Nat Immunol 2001; 2: 739–745
   PubMed Web of Science ®Google Scholar
• Meyer O, Hauptmann G, Tappeiner G, Ochs HD, Mascart-Lemone F. Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol 1985; 62: 678–684
   PubMed Web of Science ®Google Scholar
• Morgan BP, Walport MJ. Complement deficiency and disease. Immunol Today 1991; 12: 301–306
   PubMedGoogle Scholar
• Paul E, Pozdnyakova OO, Mitchell E, Carroll MC. Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 2002; 32: 2672–2679
   PubMed Web of Science ®Google Scholar
• Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001; 166: 6444–6451
   Google Scholar
• Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L. CR2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001; 15: 775–785
   PubMed Web of Science ®Google Scholar
• Carsetti R, Kohler G, Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995; 181: 2129–2140
   PubMed Web of Science ®Google Scholar
• Norvell A, Mandik L, Monroe JG. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol 1995; 154: 4404–4413
   PubMed Web of Science ®Google Scholar
• Gorelik L, Cutler AH, Thill G, Miklasz SD, Shea DE, Ambrose C, Bixler SA, Su L, Scott ML, Kalled SL. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004; 172: 762–766
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785–798
   PubMed Web of Science ®Google Scholar
• Kim SJ, Gershov D, Ma X, Brot N, Elkon KB. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 2002; 196: 655–665
   PubMed Web of Science ®Google Scholar
• Grimaldi CM, Michael DJ, Diamond B. Cutting edge: Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001; 167: 1886–1890
   PubMed Web of Science ®Google Scholar
• Zeng D, Lee MK, Tung J, Brendolan A, Strober S. Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 2000; 164: 5000–5004
   PubMed Web of Science ®Google Scholar
• Song H, Cerny J. Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. J Exp Med 2003; 198: 1923–1935
   Google Scholar
• Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004; 172: 803–811
   PubMed Web of Science ®Google Scholar
• Cariappa A, Tang M, Parng C, Nebelitskiy E, Carroll M, Georgopoulos K, Pillai S. The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity 2001; 14: 603–615
   PubMed Web of Science ®Google Scholar
• Gatto D, Pfister T, Jegerlehner A, Martin SW, Kopf M, Bachmann MF. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005; 201: 993–1005
   Google Scholar
• Brunner C, Marinkovic D, Klein J, Samardzic T, Nitschke L, Wirth T. B cell-specific transgenic expression of Bcl2 rescues early B lymphopoiesis but not B cell responses in BOB.1/OBF.1-deficient mice. J Exp Med 2003; 197: 1205–1211
   Google Scholar
• Fang Y, Xu C, Fu YX, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998; 160: 5273–5279
   PubMed Web of Science ®Google Scholar
• Barrington RA, Zhang M, Zhong X, Jonsson H, Holodick N, Cherukuri A, Pierce SK, Rothstein TL, Carroll MC. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J Immunol 2005; 175: 2859–2867
   PubMed Web of Science ®Google Scholar
• Gatto D, Pfister T, Jegerlehner A, Martin SW, Kopf M, Bachmann MF. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005; 201: 993–1005
   Google Scholar
• Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A. A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 1998; 10: 1923–1930
   Google Scholar
• Gatto D, Pfister T, Jegerlehner A, Martin SW, Kopf M, Bachmann MF. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005; 201: 993–1005
   Google Scholar
• Barrington RA, Pozdnyakova O, Zafari MR, Benjamin CD, Carroll MC. B lymphocyte memory: Role of stromal cell complement and FcgammaRIIB receptors. J Exp Med 2002; 196: 1189–1199
   PubMedGoogle Scholar
• Noorchashm H, Moore DJ, Lieu YK, Noorchashm N, Schlachterman A, Song HK, Barker CF, Naji A. Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors. Cell Immunol 1999; 195: 75–79
   PubMed Web of Science ®Google Scholar
• Jozsi M, Prechl J, Bajtay Z, Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J Immunol 2002; 168: 2782–2788
   PubMed Web of Science ®Google Scholar
• Wagner C., Ochmann C., Schoels M., Giese T., Stegmaier S., Richter R., Hug F., Hansch G.M. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol 2006; 43: 643–651
   PubMedGoogle Scholar
• Marquart HV, Svendsen A, Rasmussen JM, Nielsen CH, Junker P, Svehag SE, Leslie RG. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 101: 60–65
   PubMed Web of Science ®Google Scholar
• Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 739–747
   PubMedGoogle Scholar
• Illges H, Braun M, Peter HH, Melchers I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 2000; 122: 270–276
   Google Scholar
• Mitchell JP, Enyedy EJ, Nambiar MP, Lees A, Tsokos GC. Engagement of complement receptor 2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the increased responsiveness to antigen stimulation. Lupus 2002; 11: 299–303
   Google Scholar
• Ling N, Hansel T, Richardson P, Brown B. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 1991; 84: 16–22
   Google Scholar
• Liu YJ, Xu J, de BO, Parham CL, Grouard G, Djossou O, de Saint-Vis B, Lebecque S, Banchereau J, Moore KW. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med 1997; 185: 165–170
   PubMed Web of Science ®Google Scholar
• Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 2003; 33: 2391–2397
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23. Eur J Immunol 1996; 26: 1497–1503
   PubMed Web of Science ®Google Scholar
• Illges H, Braun M, Peter HH, Melchers I. Analysis of the human CD21 transcription unit reveals differential splicing of exon 11 in mature transcripts and excludes alternative splicing as the mechanism causing solubilization of CD21. Mol Immunol 1997; 34: 683–693
   Google Scholar
• Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis. Scand J Immunol 2004; 60: 625–630
   Google Scholar
• Masilamani M, von KJ, Illges H. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 186–190
   Google Scholar
• Grottenthaler T, Kempis J, Goldacker S, Illges H. Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int 2006; 26: 240–243
   Google Scholar
• Arora V, Verma J, Dutta R, Marwah V, Kumar A, Das N. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol. Immunol 2004; 41: 449–456
   Google Scholar
• Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991; 146: 865–869
   PubMed Web of Science ®Google Scholar
• Tsoukas CD, Lambris JD. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 1988; 18: 1299–1302
   PubMed Web of Science ®Google Scholar
• Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: Evidence for a novel transcript. J Immunol 1993; 150: 5311–5320
   Google Scholar
• Braun M, Melchers I, Peter HH, Illges H. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int Immunol 1998; 10: 1197–1202
   PubMed Web of Science ®Google Scholar
• Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM. T lymphocyte expression of complement receptor 2 (CR2/CD21): A role in adhesive cell–cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992; 90: 235–244
   PubMed Web of Science ®Google Scholar
• Marquart HV, Svehag SE, Leslie RG. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J Immunol 1994; 153: 307–315
   Google Scholar
• Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918–1927
   PubMed Web of Science ®Google Scholar
• Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970–5979
   PubMed Web of Science ®Google Scholar
• McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423–1431
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung HP, Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667–1676
   PubMed Web of Science ®Google Scholar
• Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a (CD5+B) cells make somatically hypermutated high affinity IgM rheumatoid factors. J Immunol 1993; 151: 473–488
   PubMed Web of Science ®Google Scholar
• Randen I, Mellbye OJ, Forre O, Natvig JB. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol 1995; 41: 481–486
   PubMedGoogle Scholar
• Andrews PA, Zhou W, Sacks SH. Tissue synthesis of complement as an immune regulator. Mol Med Today 1995; 1: 202–207
   Google Scholar
• Colten HR, Ooi YM, Edelson PJ. Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 1979; 332: 482–490
   PubMedGoogle Scholar
• Laufer J, Katz Y, Passwell JH. Extrahepatic synthesis of complement proteins in inflammation. Mol Immunol 2001; 38: 221–229
   PubMedGoogle Scholar
• Olmez U, Garred P, Mollnes TE, Harboe M, Berntzen HB, Munthe E. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand J Rheumatol 1991; 20: 183–189
   PubMed Web of Science ®Google Scholar
• Kemp PA, Spragg JH, Brown JC, Morgan BP, Gunn CA, Taylor PW. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol 1992; 37: 147–162
   Google Scholar
• Muso E, Sekita K, Doi T, Kuwahara T, Yoshida H, Tamura T, Kawai C, Hamashima Y. Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis. Clin Immunol Immunopathol 1984; 32: 351–358
   PubMedGoogle Scholar
• Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34–39
   PubMed Web of Science ®Google Scholar
• Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity 2004; 37: 111–123
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Moore DJ, Lieu YK, Noorchashm N, Schlachterman A, Song HK, Barker CF, Naji A. Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors. Cell Immunol 1999; 195: 75–79
   PubMed Web of Science ®Google Scholar
• Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: A role for complement. Nat Immunol 2001; 2: 739–745
   PubMed Web of Science ®Google Scholar
• Grottenthaler T, Kempis J, Goldacker S, Illges H. Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int 2006; 26: 240–243
   Google Scholar
• Masilamani M, von KJ, Illges H. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 186–190
   Google Scholar
• Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis. Scand J Immunol 2004; 60: 625–630
   Google Scholar